What is sulfadiazine?
Sulfadiazine is an antibacterial prescription medicine approved by the U.S.(FDA) for the prevention and treatment of certain types of bacterial infections, including the treatment of , Toxoplasma gondii , urinary tract infections, and other infections.
Toxoplasma gondii encephalitis can be an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo
How is sulfadiazine used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV include recommendations on the use of sulfadiazine to:
- Toxoplasma gondii encephalitis
- (also called )
- Toxoplasma gondii encephalitis from recurring
The recommended uses may not always be consistent with FDA-approved uses of sulfadiazine. See the guidelines for complete information on recommended uses of sulfadiazine in adults and adolescents with HIV. Sulfadiazine may have other recommended uses not listed above.
What should I tell my health care provider before taking sulfadiazine?
Before taking sulfadiazine, tell your health care provider:
- If you are allergic to sulfadiazine, sulfonamides (sulfa medicines), or any other medicines.
- About any medical conditions you have or have had, including the following:
- kidney or problems
- severe allergies
- blood disorders, including glucose-6-phosphate dehydrogenase (G-6PD) deficiency
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking sulfadiazine during pregnancy. The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV may include other recommendations on the use of sulfadiazine during pregnancy. Please refer to these guidelines for additional information.
- If you are breastfeeding or plan to breastfeed. For women with HIV in the United States, the Guideline does not recommend breastfeeding. Before your baby is born, or if you are already breastfeeding, talk to your health care provider to discuss alternative options for feeding your baby.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Sulfadiazine may affect the way other medicines or products work, and other medicines or products may affect how sulfadiazine works. Ask your health care provider if there are interactions between sulfadiazine and the other medicines you take.
Ask your health care provider about possible side effects from sulfadiazine. Your health care provider will tell you what to do if you have side effects.
How should I take sulfadiazine?
Take sulfadiazine according to your health care provider’s instructions. Your health care provider will tell you how much sulfadiazine to take and when to take it. Before you start sulfadiazine and each time you get a refill, read any printed information that comes with your medicine.
How should sulfadiazine be stored?
- Store sulfadiazine tablets at room temperature, 68°F to 77°F (20°C to 25°C). Protect sulfadiazine tablets from light.
- Keep sulfadiazine in the container that it came in and keep the container tightly closed.
- Do not use sulfadiazine if the original seal over the container opening is broken or missing.
- Throw away sulfadiazine that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep sulfadiazine and all medicines out of reach of children.
Where can I find more information about sulfadiazine?
More information about sulfadiazine is available:
- Recommendations on the HIV-related uses of sulfadiazine, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America
- Sulfadiazine-related research studies, from
The above Patient Version drug summary is based on the following FDA label(s): Tablet.
Last Reviewed: December 28, 2020